ArticleInvestigational new drugs2017

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Lillian M Smyth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.